Baxter reports financial results

07/22/2010 | Wall Street Journal, The

Baxter International reported a decrease in earnings for the second quarter, owing to economic and product issues. The company expects sales of its plasma protein and antibody therapy products to decline for the rest of the year because of continued market issues. It also said it has stepped up its strategies to strengthen sales of Gammagard, a plasma-based drug.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA